BC
ABBV icon

Bowman & Company’s AbbVie ABBV Stock Holding History

Bowman & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.43M Buy
10,647
+77
+0.7% +$17.5K 1.03% 28
2025
Q3 		$2.45M Sell
10,570
-22
-0.2% -$4.48K 1.03% 26
2025
Q2 		$1.97M Buy
+10,592
New +$1.97M 0.88% 29

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bowman & Company's ABBV Position: Q4 2025 in Review

Bowman & Company increased its AbbVie (ABBV) stake by 0.73% in Q4 2025, buying an estimated $17.5K and bringing the position to 10,647 shares worth $2.43M. The position accounts for 1.03% of the portfolio, ranked #28.

Bowman & Company first reported a position in ABBV in Q2 2025 and has held it in 3 quarters since. The position peaked at $2.45M in Q3 2025. 4,148 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Bowman & Company held 10,647 shares of AbbVie worth $2.43M as of Q4 2025.
  • Bowman & Company bought 77 AbbVie shares in Q4 2025, an estimated $17.5K.
  • AbbVie made up 1.03% of Bowman & Company's portfolio in Q4 2025, its #28 holding.
  • Bowman & Company first reported a position in AbbVie in Q2 2025 and has held it in 3 quarters since.
  • Bowman & Company's AbbVie position peaked at $2.45M in Q3 2025.
  • 4,148 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Bowman & Company's 13F filing for Q4 2025, filed 23 Jan 2026.